Capital deployed:

£308,000 SEIS qualifying

Use of funds:
  • Development of technology platform
  • Build sales and marketing strategies
  • Continued international expansion
  • Staff recruitment

Capital deployed:

£308,000 SEIS qualifying

Use of funds:
  • Development of technology platform
  • Build sales and marketing strategies
  • Continued international expansion
  • Staff recruitment
Mesenbio is a University of York spin-out that is developing a novel treatment for arthritis through engineered human stem cells. 

Mesenbio was founded by Professor Paul Genever and Dr David Kuntin, following more than a decade of research. The Company is developing a new treatment based on nano-sized ‘messengers’ created from engineered human stem cells that not only curb inflammation but can kick-start the process of regenerating damaged tissue.
 
DSW Ventures led a £1.4m funding round with sector specialist investor NG Bio alongside grant funding from Innovate UK. The funding will enable the company to create three new roles, develop pilot manufacturing processes, carry out pre-clinical studies and prepare the regulatory dossier in readiness for clinical trials.
Scroll to Top